15-Deoxy-Δ12,14-prostaglandin J2 inhibits glucocorticoid binding and signaling in macrophages through a peroxisome proliferator-activated receptor γ-independent process

Journal of Immunology

Volumn 172, Issue 12, 2004, Pages 7677-7683

  Cheron, Adeline ^a   Peltier, Julie ^a   Perez, Joëlle ^a   Bellocq, Agnès ^a   Fouqueray, Bruno ^a   Baud, Laurent ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,2 BIS(4 GLYCIDYLOXYPHENYL)PROPANE; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENOL DERIVATIVE; TRITIUM; UNCLASSIFIED DRUG; 15 DEOXY DELTA(12,14) PROSTAGLANDIN J2; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J2; CELL RECEPTOR; CYCLOPENTANE DERIVATIVE; CYCLOPENTENONE; DRUG DERIVATIVE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN D2; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; ARTICLE; CELL STRAIN U937; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG RECEPTOR BINDING; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSCRIPTION; GLUCOCORTICOID RESPONSIVE ELEMENT; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING; ANIMAL; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MONOCYTE; PHYSIOLOGY; RADIOASSAY;

ANIMALS; CELL LINE; CHEMOKINE CCL2; CYCLOPENTANES; DEXAMETHASONE; GLUCOCORTICOIDS; HUMANS; MACROPHAGES; MICE; MONOCYTES; PROSTAGLANDIN D2; RADIOLIGAND ASSAY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; U937 CELLS;

EID: 2942565895     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.12.7677     Document Type: Article

References (35)

1. Gilroy, D. W., P. R. Colville-Nash, D. Willis, J. Chivers, M. J. Paul-Clark, and D. A. Willoughby. 1999. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5:698.
2. 2. J. Immunol. 166:7104.
3. Lawrence, T., D. A. Willoughby, and D. W. Gilroy. 2002. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat. Rev. Immunol. 2:787.
4. Ricote, M., A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass. 1998. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79.
5. Jiang, C., A. T. Ting, and B. Seed. 2000. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82.
6. Li, M., G. Pascual, and C. K. Glass. 2000. Peroxisome proliferator-activated receptor γ-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell. Biol. 20:4699.
7. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl. Acad. Sci. USA 97:4844.
8. Rossi, A., P. Kapahi, G. Natoli, T. Takahashi, Y. Chen, M. Karin, and M. G. Santoro. 2000. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 403:103.
9. Barnes, P. J. 1998. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci. 94:557.
10. Karin, M. 1998. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 93:487.
11. Brönnegard, M. 1996. Steroid receptor number. Individual variation and down-regulation by treatment. Am. J. Respir. Crit. Care Med. 154:S28.
12. Baud, L., B. Fouqueray, A. Bellocq, S. Doublier, and J. Peltier. 2000. Inflammatory mediators modulate glucocorticoid binding and signalling. Curr. Trends Immunol. 3:177.
13. Brigino, E., S. Haraguchi, A. Koutsonikolis, G. J. Cianciolo, U. Owens, R. A. Good, and N. K. Day. 1997. Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway. Proc. Natl. Acad. Sci. USA 94:3178.
14. Bellocq, A., S. Doublier, S. Suberville, J. Perez, B. Escoubet, B. Fouqueray, D. R. Puyol, and L. Baud. 1999. Somatostatin increases glucocorticoid binding and signaling in macrophages by blocking the calpain-specific cleavage of Hsp 90. J. Biol. Chem. 274:36891.
15. Galigniana, M. D., G. Piwien-Pilipuk, and J. Assreuy. 1999. Inhibition of glucocorticoid receptor binding by nitric oxide. Mol. Pharmacol. 55:317.
16. Souque, A., J. Fagart, B. Couette, and M.-E. Rafestin-Oblin. 1996. Sulfhydryl groups are involved in the binding of agonists and antagonists to the human mineralocorticoid receptor. J. Steroid Biochem. Mol. Biol. 57:315.
17. Bellocq, A., S. Suberville, C. Philippe, F. Bertrand, J. Perez, B. Fouqueray, G. Cherqui, and L. Baud. 1998. Low environmental pH is responsible for the induction of nitric-oxide synthase in macrophages: evidence for involvement of nuclear factor-κB. J. Biol. Chem. 273:5086.
18. Wright, H. M., C. B. Clish, T. Mikami, S. Hauser, K. Yanagi, R. Hiramatsu, C. N. Serhan, and B. M. Spiegelman. 2000. A synthetic antagonist for the peroxisome proliferator-activated receptor γ inhibits adipocyte differentiation. J. Biol. Chem. 275:1873.
19. 2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPARγ-independent mechanism. Biochem. Biophys. Res. Commun. 302:415.
20. 2 are potent activators of human eosinophils. J. Immunol. 168:3563.
21. Simons, S. S., and W. B. Pratt. 1995. Glucocorticoid receptor thiols and steroid-binding activity. Methods Enzymol. 251:406.
22. 2 inhibits CD95 ligand gene expression in T lymphocytes: interference with promoter activation via peroxisome proliferator-activated receptor-γ-independent mechanisms. J. Immunol. 170:4578.
23. Kondo, M., T. Oya-Ito, T. Kumagai, T. Osawa, and K. Uchida. 2001. Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress. J. Biol. Chem. 276:12076.
24. Makino, Y., K. Okamoto, N. Yoshikawa, M. Aoshima, K. Hirota, J. Yodoi. K. Umesono, I. Makino, and H. Tanaka. 1996. Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action: cross talk between endocrine control of stress response and cellular antioxidant defense system. J. Clin. Invest. 98:2469.
25. 2 metabolite generated during inflammatory processes. J. Biol. Chem. 277:10459.
26. 2 and the ligation of PPARγ. J. Clin. Invest. 112:945.
27. Hortelano, S., A. Castrillo, A. M. Alvarez, and L. Bosca. 2000. Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages. J. Immunol. 165:6525.
28. Subbaramaiah, K., D. T. Lin, J. C. Hart, and A. J. Dannenberg. 2001. Peroxisome proliferator-activated receptor-γ ligands suppress the transcriptional activation of cyclooxygenase-2. J. Biol. Chem. 276:12440.
29. Mc Intyre, W. R., and H. H. Samuels. 1985. Triamcinolone acetonide regulates glucocorticoid-receptor levels by decreasing the half-life of the activated nuclear-receptor form. J. Biol. Chem. 260:418.
30. Webster, J. C., C. M. Jewell, J. E. Bodwell, A. Munck, M. Sar, and J. A. Cidlowski. 1997. Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J. Biol. Chem. 272:9287.
31. 2. J. Biol. Chem. 276:34082.
32. Harris, S. G., J. Padilla, L. Koumas, D. Ray, and R. P. Phipps. 2002. Prostaglandins as modulators of immunity. Trends Immunol. 23:144.
33. Okamoto, K., H. Tanaka, H. Ogawa, Y. Makino, H. Eguchi, S.-I. Hayashi, N. Yoshikawa, L. Poellinger, K. Umesono, and I. Makino. 1999. Redox-dependent regulation of nuclear import of the glucocorticoid receptor. J. Biol. Chem. 274:10363.
34. Escher, G., I. Galli, B. S. Vishwanath, B. M. Frey, and F. J. Frey. 1997. Tumor necrosis factor a and interleukin 1β enhance the cortisone/cortisol shuttle. J. Exp. Med. 186:189.
35. Berger, J., M. Tanen, A. Elbrecht, A. Hermanowski-Vosatka, D. E. Moller, S. D. Wright, and R. Thieringer. 2001. Peroxisome proliferator-activated receptor-γ ligands inhibit adipocyte IIβ-hydroxysteroid dehydrogenase type 1 expression and activity. J. Biol. Chem. 276:12629.